Business
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients\nPR Newswire\nLAS VEGAS, June 11, 2019\n\n\n\nOral thin films provide a convenient and accurate delivery system with increased bioavailability of cannabis active ingredients for patients\n LAS VEGAS, June 11, 2019 /PRNewswire/ -- GB Sciences, Inc. (OTCQB:GBLX) today announced it has obtained an exclusive license to formulate, manufacture, and sell cannabis-infused oral thin films through its MME-licensed subsidiaries and affiliates GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, and GB Sciences Las Vegas, LLC, under US Patent Number 10,265,362 B2 issued April 2019. \n\n \n \n\n \nGB Sciences' new oral thin films will be sold in Louisiana and Nevada, reflecting the company's commitment to providing advanced medical cannabis products. Oral thin films are rapidly gaining popularity due to their efficacy, convenience, and discreteness, and sales are increasing rapidly in major cannabis markets including California and Colorado.\n\"Securing this patented technology will allow us to get our patent-pending active pharmaceutical ingredients into the hands of patients in Louisiana and Nevada right away. This is great for patients, who have access to an entirely new way to consume precisely-dosed cannabis without the potential drawbacks of other delivery systems. And nobody else has this technology - making it a good mechanism for GB Sciences to further monetize its considerable intellectual property portfolio,\" explained John Poss, CEO and Chairman of GB Sciences, Inc.\n\"Oral thin films are very effective, easy to use, and have many advantages over other delivery systems on the market. We can precisely dose each strip, and patients who can't swallow will have no problem taking these,\" said Dr. Andrea Small-Howard, Chief Science Officer and Director o...